We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

MaxCyte

Commercial licence agreement with KSQ

Lighthouse | 04 December 2019

Hutchison China MediTech

Elunate (fruquintinib) secures China NRDL listing

Lighthouse | 29 November 2019

Mereo BioPharma

Setrusumab ready to advance into pivotal studies

Update | 25 November 2019

Futura Medical

Elegant and effective treatment for Erectile Dysfunction

Initiation | 25 November 2019

MaxCyte

And yet another commercial licence agreement

Update | 21 November 2019

BerGenBio

Bemcentinib NSCLC data continues to impress

Update | 19 November 2019

Bonesupport

A second consecutive quarter of record revenue

Update | 18 November 2019

Hutchison China MediTech

Acceptance of surufatintib China NDA in epNET

Lighthouse | 12 November 2019

Mereo BioPharma

Setrusumab set to advance

Lighthouse | 11 November 2019

MaxCyte

Third cohort in CARMA Phase I initiated

Lighthouse | 24 October 2019
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
142 results found.